Cart
×
Italfarmaco Community Letter – February 2021
Dear Duchenne Community, All of us at Italfarmaco would like to thank the families participating in the Phase 3 EPIDYS trial and in the open label extension study of givinostat […]
Introduction to Edgewise Therapeutics
Meet the leaders at Edgewise Therapeutics and hear their company goals related to treatments for Duchenne muscular dystrophy. You’ll be prompted to enter your name and email address to view […]
Embrace This Moment – Safety and Emergency Care Webinar
Join us as we continue this educational series through a new lens: Quality of Life. This webinar will cover the following topics:Emergency Care | Dr. Stefan Malin, MD, MSNavigating “Re-entry” […]
CureDuchenne Webinar – An Introduction to REGENXBIO and RGX-202
Learn more about REGENXBIO’s new gene therapy program for the potential treatment of Duchenne. This webinar provides an overview of the company and RGX-202, a novel, advanced micro-dystrophin gene therapy […]
CureDuchenne Webinar – Astellas Program Update
This webinar provides an update from Astellas on their study to assess the safety, tolerability, and preliminary efficacy of ASP0367 (MA-0211) for boys with Duchenne Muscular Dystrophy. You’ll be prompted […]
Letter to the Duchenne Community from PTC Therapeutics
PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to […]
CureDuchenne Webinar: COVID-19 Vaccines – What the Duchenne Community Needs to Know
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
CureDuchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollout
NEWPORT BEACH, Calif., Jan. 14, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout […]
CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophy
Newport Beach, CA (January 08, 2021) – (BUSINESS WIRE)–CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) […]